Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash from Operations (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Cash from Operations for 8 consecutive years, with 27800000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 18.31% year-over-year to 27800000.0, compared with a TTM value of 103095000.0 through Sep 2025, up 17.95%, and an annual FY2024 reading of 130901000.0, down 35.63% over the prior year.
  • Cash from Operations was 27800000.0 for Q3 2025 at X4 Pharmaceuticals, up from 29932000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 12368000.0 in Q1 2025 and bottomed at 68800000.0 in Q3 2023.
  • Average Cash from Operations over 5 years is 27366684.21, with a median of 26512000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations crashed 256.37% in 2023, then surged 63.19% in 2025.
  • Year by year, Cash from Operations stood at 19053000.0 in 2021, then decreased by 0.21% to 19093000.0 in 2022, then plummeted by 45.33% to 27747000.0 in 2023, then dropped by 18.91% to 32995000.0 in 2024, then increased by 15.74% to 27800000.0 in 2025.
  • Business Quant data shows Cash from Operations for XFOR at 27800000.0 in Q3 2025, 29932000.0 in Q2 2025, and 12368000.0 in Q1 2025.